Company overview
BrainsWay develops Deep Transcranial Magnetic Stimulation (Deep TMS) devices using patented H-Coil technology to treat mental health conditions including major depressive disorder (MDD), OCD, anxious depression, late-life depression, and smoking addiction. Their noninvasive systems feature advanced stimulators with patient management capabilities and sham-enabled options for clinical research. FDA-cleared for MDD and OCD in the US, with CE marking for additional indications in Europe.
Brainsway is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include deep tms, brainsway, transcranial magnetic stimulation, mental health devices, fda-cleared tms, ocd treatment.
Structured facts
- Website
- https://www.brainsway.com
- Markets served
- United States & Americas
- Keywords
- deep tms, brainsway, transcranial magnetic stimulation, mental health devices, fda-cleared tms, ocd treatment, depression therapy
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Frequently asked questions
- What regulatory clearances does BrainsWay Deep TMS have?
- FDA-cleared for major depressive disorder (MDD), OCD, anxious depression, late-life depression, and smoking addiction in the US; CE marked for additional psychiatric and neurological conditions in Europe.
- What are the key capabilities of BrainsWay Deep TMS systems?
- Noninvasive electromagnetic stimulation via patented H-Coils in a helmet to target deeper brain areas; includes stimulator with patient management, sham-enabled research modes, and 20-minute sessions without anesthesia.
- In which geographies is BrainsWay Deep TMS available?
- Available globally with FDA clearance in the US and CE marking in Europe; supports clinical operators worldwide through device provision and training.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
